≥97% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Argon charged,Desiccated,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3 , can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors
In Vitro
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM; 24 h) down-regulates the transcription factors Oct 4, Sox 2 and Nanog of mESCs. Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM) inhibits integrin gene expression mESC-col I (type I collagen) constructs. Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM)-treated mESC leads to the formation of aggregates and detachment from the surface. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: MESCs Concentration: 0.5 mM Incubation Time: 24 h Result: Down-regulated Oct 4, Nanog, Sox 2 by 99%, 97.5%, and 90% respectively. Up-regulated Rex1 gene expression.
In Vivo
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (0.5 mM, 24 h)-treated mESCs in the presence/absence of Leukemia inhibitory factor (LIF) (injected in both thighs) generated teratomas in severe combined immunodeficiency (SCID) mice, which indicates that the process of mESC tumor formation in vivo is dependent on integrin interaction . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:αvβ3
| Canonical Smiles | C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CS)CC2=CC=CC=C2)CC(=O)O |
|---|---|
| IUPAC Name | 2-[5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-(sulfanylmethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid |
| InChIKey | WNYJVAMZRBTOPE-UHFFFAOYSA-N |
| INCHI | 1S/C24H34N8O7S/c25-24(26)27-8-4-7-14-20(36)28-11-18(33)29-16(10-19(34)35)22(38)31-15(9-13-5-2-1-3-6-13)21(37)32-17(12-40)23(39)30-14/h1-3,5-6,14-17,40H,4,7-12H2,(H,28,36)(H,29,33)(H,30,39)(H,31,38)(H,32,37)(H,34,35)(H4,25,26,27) |
| Isomeric SMILES | C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CS)CC2=CC=CC=C2)CC(=O)O |
| PubChem CID | 22446328 |
| MeSH Entry Terms | c(RGDfC);cyclo(Arg-Gly-Asp-Phe-Cys);cyclo(arginyl-glycyl-aspartyl-phenylalanyl-cysteinyl);cyclo(RGDfC);cyclo-(Arg-Gly-Asp-D-Phe-Cys) |
| Molecular Weight | 578.64 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubility | DMSO : 50 mg/mL (86.41 mM; Need ultrasonic) |
|---|
| 1. Tiantian Zhang, Lu Zhang, Yue Shen, Haiyan Xiao, Zengsheng Han, Longgang Wang, Song Ni. (2024) Zwitterionic targeting nanodrugs prepared from poly(propyleneimine) dendrimers for enhanced anti-tumor therapy. COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, [PMID:] [10.1016/j.colsurfa.2024.134193] |
